# The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

> **NCT04929080** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 149 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinom
- Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
- **BIOLOGICAL:** JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
- **BIOLOGICAL:** JS001 and JS004

## Key facts

- **NCT ID:** NCT04929080
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2023-03-06
- **Final completion:** 2023-03-06
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04929080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04929080, "The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04929080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*